1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arecor Therapeutics plc
  6. News
  7. Summary
    AREC   GB00BMWLM973

ARECOR THERAPEUTICS PLC

(AREC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Arecor Therapeutics Initiates Early-Stage Clinical Trial for Insulin Formation

01/20/2022 | 04:47am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ARECOR THERAPEUTICS PLC -1.30% 380 Delayed Quote.-5.00%
NOVO NORDISK A/S 4.16% 761.3 Delayed Quote.-0.56%
All news about ARECOR THERAPEUTICS PLC
05/18Arecor to host kol webinar on the need for concentrated and rapid acting insulin treatm..
AQ
04/28Arecor presents full data from positive phase i clinical trial of at278 ultra-concentra..
AQ
04/28Arecor Therapeutics plc Presents Full Data from Positive Phase I Clinical Trial of AT27..
CI
04/25Earnings Flash (AREC.L) ARECOR THERAPEUTICS Reports FY21 Revenue GBP1.2M
MT
04/25Earnings Flash (AREC.L) ARECOR THERAPEUTICS Posts FY21 Loss GBP-0.27
MT
04/12Arecor Announces Oral Presentation at Attd 2022 of Phase i Clinical Trial of At278 Ultr..
AQ
03/23Arecor granted key u.s. patent protecting proprietary insulin products
AQ
03/23Arecor Therapeutics Granted Insulin Products Patents in US; Shares Up 5%
MT
01/20Business update
AQ
01/20Arecor commences us phase i clinical trial of at247 ultra-rapid insulin in combination ..
GL
More news
Financials
Sales 2021 1,16 M 1,45 M 1,45 M
Net income 2021 -6,65 M -8,29 M -8,29 M
Net cash 2021 17,3 M 21,6 M 21,6 M
P/E ratio 2021 -11,5x
Yield 2021 -
Capitalization 106 M 132 M 132 M
EV / Sales 2021 76,0x
EV / Sales 2022 60,4x
Nbr of Employees 37
Free-Float 64,0%
Chart ARECOR THERAPEUTICS PLC
Duration : Period :
Arecor Therapeutics plc Technical Analysis Chart | AREC | GB00BMWLM973 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 380,00 GBX
Average target price 528,00 GBX
Spread / Average Target 38,9%
EPS Revisions
Managers and Directors
Sarah Jennifer Howell Chief Operating Officer & Executive Director
Susan Day Lowther Chief Financial Officer, Secretary & Director
Andrew John McGlashan Richards Non-Executive Chairman
Jan Jezek Chief Scientific Officer
Lindsey Foulkes Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ARECOR THERAPEUTICS PLC-5.00%134
MODERNA, INC.-46.35%57 031
LONZA GROUP AG-29.91%40 761
IQVIA HOLDINGS INC.-28.46%38 185
SEAGEN INC.-9.68%26 255
ICON PUBLIC LIMITED COMPANY-30.22%17 418